CJC-1295 and Ipamorelin: what the research actually says

CJC-1295 and Ipamorelin are almost always discussed as a pair, sold as a "stack" aimed at raising growth hormone for muscle gain, fat loss, sleep, and recovery. They're actually two distinct molecules that work through different receptors, and neither has been through the kind of testing that would establish it works or is safe in people for these purposes. Here is what the peer-reviewed literature and federal regulators actually say.

What each compound is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to secrete growth hormone. Natural GHRH is degraded quickly in the bloodstream; CJC-1295 was engineered with modifications — including an optional Drug Affinity Complex (DAC) technology — to resist that degradation and stay active much longer. A 2006 Phase I pharmacokinetic trial in healthy adults (ages 21–61) published in the Journal of Clinical Endocrinology & Metabolism found the estimated half-life of CJC-1295 to be 5.8–8.1 days, compared with minutes for natural GHRH.² That longevity is part of its appeal and part of its risk: if something goes wrong, there is no short-acting window in which to stop the effect.

Ipamorelin is a pentapeptide (five amino acids) that mimics ghrelin and activates a separate receptor on the pituitary gland — the growth hormone secretagogue receptor — also triggering growth hormone release. It was characterized in a 1998 study published in the European Journal of Endocrinology as "the first selective growth hormone secretagogue," notable for not significantly raising cortisol or ACTH even at doses more than 200-fold higher than its growth-hormone-releasing ED50 in swine — a selectivity profile that distinguished it from older growth-hormone-releasing peptides like GHRP-2 and GHRP-6.⁵ That study was conducted in rats and pigs, not people.

The theoretical rationale for stacking them

GHRH analogs (like CJC-1295) and growth hormone secretagogues (like Ipamorelin) act on two distinct receptor pathways that converge on the same pituitary output: growth hormone secretion. The theory behind combining them is additive or synergistic stimulation — hitting both pathways at once to produce a larger GH pulse than either compound could generate alone. This dual-pathway hypothesis is grounded in legitimate pharmacological reasoning. The problem is that it has not been validated in human beings for physique or performance purposes. The only human data comes from the CJC-1295 monotherapy trial, not the combined stack, and that trial was a pharmacokinetic safety study, not an efficacy study for muscle gain or fat loss.

What the evidence shows: compound by compound

CJC-1295: the human pharmacokinetic data

The single published Phase I trial of CJC-1295 in humans — a randomized, placebo-controlled, double-blind, ascending-dose study by Teichman et al. (2006) in the Journal of Clinical Endocrinology & Metabolism — enrolled 64 subjects (healthy adults, ages 21–61) and tested single and multiple-dose regimens.² After a single injection, mean plasma GH concentrations increased 2- to 10-fold for 6 days or more. Mean plasma IGF-I concentrations rose 1.5- to 3-fold and remained elevated for 9–11 days. After multiple doses, mean IGF-I levels stayed above baseline for up to 28 days. No serious adverse reactions were reported in the trial itself — but this was a short-term, small-sample pharmacokinetic study, not a long-term safety or efficacy trial. What the data showed was that the drug measurably alters GH and IGF-1 levels; it did not establish that doing so is beneficial or safe over months or years of self-administration at unverified doses from unregulated sources.

Ipamorelin: only preclinical data for performance purposes

Despite widespread use in the wellness and bodybuilding space, Ipamorelin has no published, controlled human trials establishing efficacy for performance or body composition. Its pharmacological profile was established in rats and swine. The only human context in which it was studied — and in which serious safety signals emerged — was an intravenous trial for gastric motility, a completely different indication and route of administration than the subcutaneous self-injection common in wellness settings. The FDA reviewed that literature and found "serious adverse events including death" associated with IV Ipamorelin.⁴

The combination: animal data only

A 2026 structured narrative review in JBJS Reviews surveyed the contemporary evidence for injectable peptides in sports medicine and found that CJC-1295 combined with ipamorelin "showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies."³ The combination has not been tested in controlled human trials for any athletic, physique, or recovery indication as of the date of this page.

Regulatory status: FDA

Neither CJC-1295 nor Ipamorelin is an FDA-approved drug for any indication in the United States. Both appear on the FDA's list of bulk drug substances that may present significant safety risks in compounding.⁴

• CJC-1295 (listed under 503A/503B Category 2): FDA identified "serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction" and noted that "available clinical data are limited."
• Ipamorelin acetate (503B Category 2, added September 29, 2023): FDA found compounded Ipamorelin acetate "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities." Ipamorelin acetate also "contains unnatural amino acids, which add to the complexity of peptide characterization."

Despite these flags, both compounds continue to circulate in the gray market labeled "research use only" — a label that does not create legal permission for human use and does not reflect any regulatory review of the product's quality, purity, or potency.¹

"Insulin and GLP-1s are designed for specific disease, so we know who's a good candidate for them. With these newer peptides, we don't have the same level of evidence yet."

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, in the American Medical Association (April 2026)

Doping status: WADA and sport

Both CJC-1295 and Ipamorelin are explicitly named in the 2026 peer-reviewed doping literature as substances of concern in competitive and recreational sport.⁶ Under the World Anti-Doping Agency's Prohibited List, GHRH analogs (the class CJC-1295 belongs to) and growth hormone secretagogues (the class Ipamorelin belongs to) both fall under S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — and are prohibited both in and out of competition.

Detection of these compounds presents ongoing challenges for anti-doping authorities because their structural similarity to endogenous hormones and short biological windows complicate urinalysis, but WADA has expanded its detection methodologies in response to growing use. The 2026 doping review in the Journal of Sports Medicine and Physical Fitness notes that "analytical challenges remain due to peptides' structural similarity to endogenous hormones and short half-lives," while pointing out that CJC-1295 is a partial exception: its long half-life (5.8–8.1 days) makes it more detectable than shorter-acting peptides.⁶

Safety: what is and is not known

A 2026 narrative review of performance-enhancing peptides modulating the GH-IGF-1 axis in Frontiers in Endocrinology catalogued the reported adverse effects associated with compounds in this class: "endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions."⁷ For the specific combination of CJC-1295 and Ipamorelin, long-term safety data — including on insulin sensitivity, fluid retention, joint symptoms, and potential mitogenic (cell-growth-stimulating) effects of chronically elevated IGF-1 — are simply absent. There are no multi-year human studies on this stack.

The 2026 doping review adds several more concerns specific to the class: "cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability." It also flags the unregulated supply chain as a compounding risk factor, noting that "products are often mislabeled or contaminated."⁶ As with any unregulated injectable, contamination and inaccurate labeling introduce additional layers of risk independent of whatever the labeled compounds themselves might do.

Dr. Tam's broader point applies directly: "unfortunately, there just isn't enough valuable, statistically significant evidence that points us to be able to recommend them safely."⁸

What researchers and clinicians say about the evidence gap

The mismatch between the pace of self-administration and the pace of scientific evidence is a recurring theme in the 2026 literature. The Frontiers in Endocrinology review frames the entire field as "bridging the gap between clinical evidence and patient self-administration" — meaning people are widely using these compounds in the complete absence of the trials that would be required to establish whether they work or what they do.⁷

The JBJS Reviews 2026 structured narrative review of injectable peptides in sports medicine concludes that "injectable peptides for sports medicine remain largely experimental" and that "clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols." It explicitly recommends that clinicians caring for athletes counsel patients about "uncertain efficacy, product quality, safety risks, and antidoping implications."³

If you're considering it anyway

If your interest is in growth hormone, body composition, or recovery, a licensed physician can evaluate whether you have a diagnosable condition — such as adult-onset GH deficiency or HIV-associated lipodystrophy — for which an FDA-approved option exists. Tesamorelin, for example, is an FDA-approved GHRH analog with controlled trials behind it for specific indications. See our safest way to try peptides guide for how to find a telehealth provider who works within the regulated system and can order the bloodwork to determine whether there is a real deficiency worth treating. Understanding what peptides are and how they differ from approved drugs is a useful starting point before any conversation with a provider.